Company
Enzymatica AB
Headquarters: Lund, Sweden
Employees: 26
CEO: Ms. Therese Filmersson
Market Cap
kr430.0 Million
SEK as of July 1, 2024
US$40.5 Million
Enzymatica AB Categories
Sweden Healthcare Drug Manufacturers—Specialty & GenericSweden Healthcare Sweden Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.
Stocks & Indices
Enzymatica AB has the following listings and related stock indices.
Stock: OMX: ENZY wb_incandescent
Stock: FSX: EN9 wb_incandescent